Enzyme-replacement therapy for metabolic storage disorders

Lancet Neurology

Volumn 3, Issue 12, 2004, Pages 752-756

  Brady, Roscoe O ^a,b   Schiffmann, Raphael ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTITHROMBOCYTIC AGENT; ENZYME; GLUCOSYLCERAMIDASE; LEVO IDURONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE;

ANEMIA; BONE DISEASE; BRAIN INJURY; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; ENZYME REPLACEMENT; EYE INJURY; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART INJURY; HEPATOSPLENOMEGALY; HUMAN; HURLER SYNDROME; JOINT INJURY; KIDNEY INJURY; LIVER INJURY; MAROTEAUX LAMY SYNDROME; MYOPATHY; NONHUMAN; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; REVIEW; SCHEIE SYNDROME; SIDE EFFECT; STORAGE DISEASE; THROMBOCYTOPENIA;

EID: 8844253982     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00938-X     Document Type: Short Survey

References (36)

1. Whybra C, Kampmann C, Krummenauer F, et al. The Mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 65:2004;299-307
2. Hers HG. Alpha-glucosidase deficiency in generalized glycogen storage disease (Pompe disease). Biochem J. 86:1963;11-16
3. Trams EG, Brady RO. Cerebroside synthesis in Gaucher's disease. J Clin Invest. 39:1960;1546-1550
4. Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun. 18:1965;221-225
5. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficency. N Engl J Med. 276:1967;1163-1167
6. Bach G, Friedman R, Weissman B, Neufeld EF. The defect in Hurler and Scheie syndrome: deficiency of α-L-iduronidase. Proc Natl Acad Sci USA. 69:1972;2048-2051
7. Matalon R, Dorfman A. Hurler's syndrome, an alpha-L-iduronidase deficiency. Biochem Biophys Res Commun. 47:1972;959-964
8. de Duve C. From cytases to lysosomes. Fed Proc. 23:1964;1045-1049
9. Brady RO, Tallman JF, Johnson WG, et al. Replacement therapy for inherited enzyme deficiency: use of purified ceramidetrihexosidase in Fabry's disease. N Engl J Med. 289:1973;9-14
10. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med. 291:1974;989-993
11. Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta. 673:1981;425-434
12. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher. s disease. N Engl J Med. 324:1991;1464-1470
13. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in Gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Int Med. 122:1995;33-39
14. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α- galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA. 97:2000;365-370
15. Eng CM, Banikazemi M, Gordon R, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 68:2001;711-722
16. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA. 285:2001;2743-2749
17. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase A therapy in Fabry's disease. N Engl J Med. 345:2001;9-16
18. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 75:2004;65-74
19. Moore DF, Scott L, Gladwin MT, et al. Regional cerebral hyper-perfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 104:2001;1506-1512
20. Moore DF, Ye F, Brennan M-L, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging. 2:2004;674
21. Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study. J Inherit Metab Dis. 26:2003;617-627
22. Weidemann F, Breuning F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease; a prospective strain rate imaging study. Circulation. 108:2003;1299-1301
23. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve. 28:2003;703-710
24. Hilz MJ, Brys H, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy. Neurology. 62:2004;1066-1072
25. Linthorst GE, Hollak CEM, Donker-Koopman WE, Stijland A, Aerts JMFG. Enzyme therapy for Fabry disease: neutralizing antibodies towards agalsidase alpha and beta. Kidney Int. 66:2004;1589-1595
26. Amalifitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 3:2001;132-138
27. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human a-glucosidase from milk. Pediatrics. 113:2004;e448-457
28. Winkel LP, Van den Hout JM, Kamphoven JH, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol. 55:2004;495-502
29. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 344:2001;182-189
30. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr. 144:2004;581-588
31. Harmatz P, Whitley CB, Waber L, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 144:2004;574-580
32. Clarke JT, Amato D, Deber RB. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario. CMAJ. 165:2001;595-596
33. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther. 2:2002;325-333
34. Meikle PJ, Fietz MJ, Hopwood JJ. Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev Mol Diagn. 4:2004;677-691
35. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine. 81:2002;122-138
36. Cox T, Lachmann R, Hollak, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 355:2000;1481-1485